Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
|Articles|May 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 5
- Volume 17
- Issue 5
First trial of RXR agonist
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204.
Advertisement
IRVINE, California-NuRx Pharmaceuticals, Inc. has dosed the first patient in a single-center phase I clinical trial of its first-in-class rexinoid receptor (RXR) agonist NRX4204. In preclinical studies, the orally bioavailable RXR agonist was effective in models of non-small-cell lung cancer and breast cancer.
Articles in this issue
over 18 years ago
Immunotherapy agent promising in NSCLCover 18 years ago
NCCN greenlights nilotinib for imatinib-resistant CML patientsover 18 years ago
No overall survival benefit for dose-intense regimen in SCLCover 18 years ago
Make a note of new smoking cessation codesover 18 years ago
Relistor for treating OICover 18 years ago
Experts argue against need for phase III proton Rx trialsover 18 years ago
Spotlight on Cancer Centersover 18 years ago
Novel peptide vaccine promising in myeloid leukemiaover 18 years ago
Intensive imatinib/chemo ups EFS in pediatric Ph+ ALLAdvertisement
Related to this article
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus nivolumab caused no unexpected safety signals.
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and other areas in myelofibrosis.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
3
Proton Therapy Tied to Less Hypothyroidism After Supraclavicular Breast RT
4
ASH Issues New Myelofibrosis Guidelines With 10 Management Recommendations
5